Novel Cholesterol treatment is a rising star-Anacetrapib update
New era in cholesterol treatment may have dawned at the American Heart Association Meeting in Chicago. From the Late Breaking Clinical Trials session on the last day of the meeting, a Cholesteryl Ester Transfer Protein inhibitor known as anacetrapib was found to avoid the problems of a prior attempt in this family (torcetrapib) and the presenters resoundingly recommended that further studies commence!
Raising good cholesterol to a significant degree can presently only be accomplished with Niacin or exercise. HDL acts as a key dump truck in our body, taking cholesterol from the circulation to the liver where it can be made into useful products or removed.
A new era in cholesterol treatment may have dawned at the American Heart Association Meeting in Chicago. From the Late Breaking Clinical Trials session on the last day of the meeting, a Cholesteryl Ester Transfer Protein inhibitor known as anacetrapib was found to avoid the problems of a prior attempt in this family (torcetrapib) and the presenters resoundingly recommended that further studies commence!
I expect that the FDA will give this new drug fast track status (see www.fda.gov) and a brand new family of medicines will be born. The old target was bad cholesterol (LDL) and the new mantra will be LDL lowering and HDL raising combination therapy!